NCT04708067 2026-03-05
Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT03620201 2024-10-22
M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04349280 2024-04-18
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT04551950 2024-03-08
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
EMD Serono
Phase 1 Completed
NCT04756505 2023-12-27
Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04457778 2023-12-08
First in Human Study of M6223
EMD Serono
Phase 1 Completed
NCT03524170 2022-03-07
Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04296942 2022-01-11
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated